Posts Tagged ‘ABT’

Abbott Labs Puts Active After Q4 Earnings

Shares in Abbott Laboratories (Ticker: ABT) are in negative territory on Wednesday after the company reported better than expected fourth-quarter earnings, but revenue that was less than analysts estimated. Shares in the medical products company dropped 5.5% to an intraday low of $36.94 near the open, but have rallied significantly during the session to stand at $38.40 as of the time of this writing.

Options changing hands on Abbott Labs in the early going suggests some traders are positioning for the price of the underlying to potentially extend losses this week. The 24 Jan ’14 weekly puts traded more than 1,600 times this morning against open interest of 204 contracts. Time and sales data indicates most of the volume was purchased for an average premium of $0.45 each. Put buyers stand ready to profit at expiration this week in the event that ABT shares slip 2.2% from the current level of $38.40 to breach the breakeven point on the downside at $37.55.

The regular Mar $37 strike puts attracted fresh interest as well during the first half of the session, with around 440 contracts purchased at a premium of $0.74 each. These puts make money if shares move 5.5% lower to trade below $36.26 by March expiration. Put options are more active than calls on Abbott this morning, with the put/call ratio hovering near 1.4 just before midday in New York trading.  


Tags:




Wrong Way Weekly Wrap-Up

I am trying to get bullish, really I am.

As I said to Members on Thursday morning in chat, like Sam Jackson in Pulp Fiction: "I'm trying hard to be the (bullish) shepherd" but the data makes it hard – so very hard!  Anyway, I'm not here to complain about the market forces moving against us but to review the carnage of our picks going all the way back to Sept 10th, when we decided the prior day's beige book was not going to be enough to break out over 9,600 on the Dow.  Now, with the Dow at 9,820 after testing 9,900 it's a good idea to look back and see what we missed in this last 2.5% leg up

On Thursday the 10th, we talked about patterns.  One pattern I recommended following right in the morning post was the famous "stick save" investment.  Simply buying high-delta DIA calls at about 2:30 each afternoon and selling into the pumped-up close.  That was a winning play on the 10th, 11th (Fri), 14th and 16th but not the last two days, when we turned a lot more bearish – but we'll get to that further down this review. 4 out of 5 days is pretty good for a patten and seeing it broken 3 of the past 5 days is also significant.  I did promise that Thursday that we will look for more bullish opportunities once we have a clear break over our last two levels (NYSE 6,959 and S&P 1,056) and we did make those this week.  If we hold it through Tuesday, it will be time and we're going to line up some trades this weekend.  True to my word on that Thursday, we chose a variety of bullish and bearish plays in Member Chat.  I'm posting the plays along with suggested adjustments if needed as it's a nice way to review our various strategies in progress – especially under "adverse" conditions.

Trade ideas of the day for Members were:

  • DIA $95 puts that ended up being rolled and doubled down for a net 20% gain (too much bother to detail).
  • SUN at $23.36, now $28.45 (up $5.09), short Oct $25 calls at $2.20, now 3.70 (down $1.50) and short the Jan $22.50 puts at $1.15, now .70 (up .45).

    • Another buy/write at net $23.01/22.76, already


continue reading


Tags: , , , , , , , , , , , , , , , , , , , , , ,




Pharma’s Green Shoots

Courtesy of Pharmboy

Hello all! Not a bad month since our first plays in the Pharma and Biotech space. Phil summed up last week the positions and the nice profits on our picks, and I think it is time for a few more companies to focus on for our virtual portfolios (e.g., 100K), after all, it’s about tilling the soil and making some money on our Pharm…. 

First, the healthcare debate is going to rage on after the holiday weekend, and I am expecting this sector to take some lumps with our good ride up. I would expect the economies of scale to weigh in, as even though price may be lower, picking up more coverage (patients) is what it is all about. Those dependent upon high priced biologics may be the ones that take the biggest hit, as the costs are quite different than popping a pill every day for a few $$$. Just things to ponder and we will react as developments take shape on the horizon.

Mid-summer and early fall are the times for the biotech and pharma segments to provide the greatest returns. I cannot decide if it is the cyclical nature or if more clinical data are being released during this time. Looking at XBI and XPH over a five year period, the biotech fund (XBI) has done a bit better on overall return, but the two charts follow the same overall pattern. Thus, we are entering the final stretch for this sector, and should be prepared for a slight pullback during the holidays.

5 yr XBI and XPH Chart Here >>

Now, on to the good stuff….

Shire PLC (SPHGY), founded in 1986, aims to be a market leader in meeting the needs of specialist physicians in targeted segments. Its core therapeutic focus areas are attention deficit hyperactivity disorder (ADHD; within central nervous system, CNS) and increasingly biopharmaceuticals that address specific genetic disorders. Consistent with this strategy, Shire has been made a number of important acquisitions, including the 2007 purchase of New River, the developer of Vyvanse (the successor for Adderall XR ADHD treatment; and a series of biopharmaceutical acquisitions, following the Transkaryotic Therapies entry acquisition in 2005. In 2008, Shire acquired German biotech company Jerini, which brought along Firazyr, a treatment for hereditary angioedema. 

Recently, Shire has sent its treatment for Gaucher disease, an alternative…
continue reading


Tags: , , , , , , ,




 
 
 

Zero Hedge

The Fed Is Stuck In QE Hell

Courtesy of Zero Hedge. View original post here.

Authored by Howard Gold, op-ed via MarketWatch.com,

Imagine doing the same thing over and over again, with little progress and no relief. Sounds like most people’s vision of hell - or the Federal Reserve’s current predicament.

Since September, the central bank, through the Federal Reserve Bank of New York, has been purchasing securities hand over fist to alleviate short-term pressures in the overnight money markets. It has used repurchase (“repo”) and reverse repurchase (“reverse repo”) agreements to provide liquidity and keep overnight borrowing rates from spiking.

...



more from Tyler

Phil's Favorites

Baltic Dry Continues Epic Plunge As IMF Slashes Global GDP Forecast

Courtesy of ZeroHedge

The Baltic Exchange's main sea freight index hit a nine-month low on Monday, dragged down by falling rates of capesize and panamax segments as world trade continues to slump. 

The Baltic Dry Index, which tracks rates for capesize, panamax and supramax vessels that ferry dry bulk commodities across the world, dropped 25 points, or 3.3%, to 729 (according to Refinitiv data), the lowest level since April 2019:

  • The capesize index .BACI dropped 119 points, or 16.7%, to 593 - its lowest since April 23.The index registered its 27th straight session of losses, and also its largest daily percentage loss since early April.

    ...


more from Ilene

The Technical Traders

Using the copy-paste formula in the Forex market

Courtesy of Technical Traders

In Forex there are many techniques available to boost up the profit factors. However, as there are millions of people trying to make a profit it is not easy to get the right tricks. There are many brokers offering high leverage trading account to the interested traders. They also provide useful insight into the market so that the traders can make a decent profit. In fact, some brokers often sell signals to their clients so that they can start earning money in the early stage of their careers.

At present, this method has earned a huge following as many investors don’t like to spend time staring at the chart. In this article, we are going to try to bust the myth about this infamous technique...



more from Tech. Traders

Members' Corner

The War on All Fact People

 

David Brin shares an excerpt from his new book on the relentless war against democracy and how we can fight back. You can also read the first, second and final chapters of Polemical Judo at David's blog Contrary Brin.

The War on All Fact People 

Excerpted from David Brin's new book, the beginning of chapter 5, Polemical Judo: Memes...



more from Our Members

Chart School

SP500 Kitchin Cycle Review

Courtesy of Read the Ticker

The biggest known news date in the next 18 months is the US Election. The biggest unknown news date is when the US believes it is in a economic recession.

The Kitchin Cycle is still working.

We must conclude the major 900 period low is now in, and we are now in a up swing, which may top out ate 2020 or late 2021. Any future top out may only generate a 10% to 20% correction, of course this can be deemed very mild. This is expected, but the expected does always play out. 

Rolling the dice to get '7' does not always work. Post US elections seasonal's aligned with a poor start of the decade seasonal trends, add on high global recession risk, add on a stock market slump tends to occur in the years ending 9,1,2,3,4 (like 1973, 1...



more from Chart School

Insider Scoop

10 Biggest Price Target Changes For Friday

Courtesy of Benzinga

  • Citigroup lifted Caterpillar Inc. (NYSE: CAT) price target from $145 to $170. Caterpillar closed at $147.87 on Thursday.
  • UBS cut Twitter Inc (NYSE: TWTR) price target from $37 to $35. Twitter shares closed at $34.19 on Thursday.
  • Morgan Stanley boosted the price target for Yum! Brands, Inc. (NYSE: YUM) from $113 to $118. Yum! Brands closed at $102.16 on Thursday.
  • Jefferies lifted the price target on Ventas, Inc. (NYSE: ...


http://www.insidercow.com/ more from Insider

Kimble Charting Solutions

Tesla About To Run Out Of Energy Here? Short-Term Peak Possible?

Courtesy of Chris Kimble

Tesla (TSLA) has been screaming higher of late, as very impressive gains have taken place.

Is Tesla about to run out of energy/take a break/experience some selling pressure? A unique price setup is in play, that bulls might want want to be aware of.

This chart applies Fibonacci to the 2016 lows and 2017 highs at each (1). The impressive rally of late has it testing its 161% extension level, based upon those price points.

At the same time, it is hitting its 161% extension level, it finds itself at the top of a 7-year rising channel, with momentum hitting the highest ...



more from Kimble C.S.

Lee's Free Thinking

Why Blaming the Repo Market is Like Blaming the Australian Bush Fires

 

Why Blaming the Repo Market is Like Blaming the Australian Bush Fires

Courtesy of  

The repo market problem isn’t the problem. It’s a sideshow, a diversion, and a joke. It’s a symptom of the problem.

Today, I got a note from Liquidity Trader subscriber David, a professional investor, and it got me to thinking. Here’s what David wrote:

Lee,

The ‘experts’ I hear from keep saying that once 300B more in reserves have ...



more from Lee

Digital Currencies

Cryptos Have Surged Since Soleimani Death, Bitcoin Tops $8,000

Courtesy of ZeroHedge View original post here.

Bitcoin is up over 15% since the assassination of Iran General Soleimani...

Source: Bloomberg

...topping $8,000 for the first time since before Thanksgiving...

Source: Bloomberg

Testing its key 100-day moving-average for the first time since October...

...



more from Bitcoin

Biotech

Why telling people with diabetes to use Walmart insulin can be dangerous advice

Reminder: We are available to chat with Members, comments are found below each post.

 

Why telling people with diabetes to use Walmart insulin can be dangerous advice

A vial of insulin. Prices for the drug, crucial for those with diabetes, have soared in recent years. Oleksandr Nagaiets/Shutterstock.com

Courtesy of Jeffrey Bennett, Vanderbilt University

About 7.4 million people ...



more from Biotech

Mapping The Market

How IPOs Are Priced

Via Jean Luc 

Funny but probably true:

...

more from M.T.M.

Promotions

Free eBook - "My Top Strategies for 2017"

 

 

Here's a free ebook for you to check out! 

Phil has a chapter in a newly-released eBook that we think you’ll enjoy.

In My Top Strategies for 2017, Phil's chapter is Secret Santa’s Inflation Hedges for 2017.

This chapter isn’t about risk or leverage. Phil present a few smart, practical ideas you can use as a hedge against inflation as well as hedging strategies designed to assist you in staying ahead of the markets.

Some other great content in this free eBook includes:

 

·       How 2017 Will Affect Oil, the US Dollar and the European Union

...

more from Promotions





About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>